Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges
CUE•Analyst view
The one available analyst rating on the shares is buy. The average consensus recommendation for the biotechnology and medical research peer group is also buy.
Wall Street's median 12-month price target for Cue Biopharma, Inc. is $115.00, about 270% above its August 13 closing price of $31.08.
Clinical outlook and financing
Cue Biopharma expects CUE-221 Phase 2 data by the end of Q3 2026 and plans to initiate a CUE-401 Phase 1 study by year-end 2026.
The company also completed a $50 million private placement after quarter-end to fund clinical development.
Q2 revenue more than doubles on collaboration milestone
Cue Biopharma said second-quarter revenue more than doubled year over year, driven by milestone collaboration payments.
- Q2 collaboration revenue: $7.88 million
- The increase was driven by a milestone payment from the Boehringer Ingelheim collaboration and license agreement.
